Microbiology Testing/Clinical Microbiology Market by Application, Disease, Product and End User – Global Forecast to 2023

DUBLIN–(BUSINESS WIRE)–The “Microbiology
Testing/Clinical Microbiology Market by Application, Disease, Product,
End User – Global Forecast to 2023”
report has been added to ResearchAndMarkets.com’s
offering.

The global clinical microbiology market is expected to reach USD 4.95
billion by 2023 from USD 3.63 billion in 2018, growing at a CAGR of 6.4%.

The technological advancements in disease diagnostics, rising incidence
of infectious diseases and growing outbreak of epidemics, and increased
funding and public-private investments in the field of disease diagnosis
are the key factors driving the growth of this market. While the market
is expected to grow at a steady rate in the next five years, factors
such as reimbursement concerns and unfavorable regulatory scenario in
some nations are expected to restrict market growth.

On the basis of products, the market is categorized into instruments
(laboratory instruments and microbiology analyzers) and reagents
(pathogen-specific kits and general reagents). The instruments segment
is expected to account for the largest share of the global clinical
microbiology market in 2018. Factors such as the significant adoption of
conventional laboratory instruments among end users, technological
advancements in the field of molecular techniques proteomics (such as
the integration of microfluidics with PCR and nanotechnology with qPCR
techniques), and the ongoing trend of laboratory automation among
clinical laboratories, are propelling growth in this segment.

The instruments product segment is further subsegmented into laboratory
instruments (incubators, gram stainers, autoclave sterilizers, bacterial
colony counters, microbial air samplers, blood culture counters,
microbial culture systems, anaerobic culture systems, petri dish
fillers, and other laboratory instruments) and microbiology analyzers
(molecular diagnostic instruments, advanced microscopes, and mass
spectrometers). The microbiology analyzers product segment is expected
to grow at highest CAGR during the forecast period. This can be
attributed to the increasing adoption of advanced analyzers for disease
diagnosis by end users, and technological advancements in the field of
molecular diagnostic instruments.

Similarly, the reagents product segment is further subsegmented into
pathogen-specific kits and general reagents. The pathogen-specific kits
segment is expected to grow at higher CAGR during the forecast period.
The growth of this segment is attributed to factors such as the
flexibility pathogen-specific kits offer to end users to optimize the
reaction for better results and increasing patient preference across
major countries for early and accurate disease diagnosis.

On the basis of disease area, the clinical microbiology market is
segmented into respiratory diseases, bloodstream infections (BSIs),
gastrointestinal (GI) diseases, sexually transmitted diseases (STDs),
urinary tract infections (UTIs), periodontal diseases, and other
diseases (including cardiovascular disease, central nervous system
infections, connective tissue joint diseases, and skin diseases). The
respiratory disease segment is estimated to witness the highest growth
during the forecast period, primarily due to as the large patient
population suffering from respiratory diseases (coupled with the growing
exposure to key risk factors such as pollution) and the increasing
number of epidemic outbreaks of respiratory infections.

On the basis of end user, the clinical microbiology market is segmented
into hospitals and diagnostic centers, custom lab service providers, and
academic and research institutes. The custom lab service providers
segment is estimated to witness the highest growth during the forecast
period owing to the continuous outsourcing of drug testing procedures to
laboratory service providers by pharmaceutical companies, procedural
benefits offered by advanced molecular technology-based instruments
(such as PCR and NGS) in drug discovery, increasing number of
microbiology-based clinical trials, and the growing number of custom lab
service providers across major markets.

Product launches and enhancements are the key growth strategies adopted
by major players to strengthen their position in the global microbiology
testing/clinical microbiology market. In addition, strategies such as
agreements, partnerships, and collaborations; acquisitions; and
expansions were also adopted by several market players to remain
competitive in the market.

Market Dynamics

Drivers

  • Technological Advancements in Disease Diagnostics
  • Rising Incidence of Infectious Diseases and Growing Outbreaks of
    Epidemics
  • Increased Funding and Public-Private Investments

Restraints

  • Limited Reimbursement Policies for Microbiology Testing Procedures
  • Unfavorable Regulatory Scenario

Opportunities

  • Improving Healthcare Infrastructure Across Emerging Countries

Challenges

  • Operational Barriers Related to the Use of Diagnostic Tests
  • Bundled Sales of Microbiology Testing Products – A Key Challenge for
    Small and Emerging Reagent Manufacturers

Key Topics Covered

2 Research Methodology

3 Executive Summary

4 Premium Insights

5 Market Overview

6 Microbiology Testing Market, By Application

7 Clinical Microbiology Market, By Product

8 Clinical Microbiology Market, By Disease Area

9 Clinical Microbiology Market, By End User

10 Microbiology Testing/Clinical Microbiology Market, By Region

11 Competitive Landscape

12 Company Profiles

  • bioMerieux
  • Danaher Corporation
  • Becton, Dickinson and Company
  • Abbott
  • Roche Diagnostics (A Subsidiary of F. Hoffmann-La Roche Ltd.)
  • Bruker
  • Hologic
  • Bio-Rad
  • Qiagen
  • Thermo Fisher Scientific
  • Agilent
  • Merck KGaA
  • Shimadzu
  • 3M
  • Neogen

For more information about this report visit https://www.researchandmarkets.com/research/25c6j9/microbiology?w=4

الموقع يستعمل RSS Poster بدعم القاهرة اليوم